Breaking News

ICON plc Selected by BARDA to Execute Anthrax Vaccine Clinical Trial

BARDA is providing funding to develop and execute a clinical trial that will evaluate the immune response to AV7909.

Author Image

By: Charlie Sternberg

Associate Editor

ICON plc a healthcare intelligence and clinical research organization, has been selected by the US Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the Department of Health and Human Services (HHS), to execute an anthrax vaccine clinical trial.   BARDA is providing funding to the Government and Public Health Solutions team at ICON to develop and execute a clinical trial that will evaluate the immune res...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters